Two-stage interaction of the tumor nursing galectin-1 with the antiangiogenic peptide anginex

被引:0
作者
Zsófia Hegedüs
Edit Wéber
Lea Végh
Balázs Váczi
Vilmos Tubak
Éva Kriston-Pál
Zoltán Kele
Éva Monostori
Tamás A. Martinek
机构
[1] University of Szeged,SZTE
[2] Biological Research Center of the Hungarian Academy of Sciences,MTA Lendulet Foldamer Research Group, Institute of Pharmaceutical Chemistry
[3] University of Szeged,Lymphocyte Signal Transduction Laboratory, Institute of Genetics
[4] University of Szeged,Department of Medical Chemistry
来源
Journal of Thermal Analysis and Calorimetry | 2015年 / 120卷
关键词
Isothermal titration calorimetry; Anginex; Galectin-1; Angiogenesis;
D O I
暂无
中图分类号
学科分类号
摘要
The 33mer peptide anginex is a potent inhibitor of angiogenesis and tumor growth. Its biological activity is dependent on the β-galactoside-binding protein galectin-1 (gal-1), which has been reported to be the main receptor for anginex. The gal-1–anginex interaction has been observed using surface plasmon resonance and mass spectrometric methods, but the stoichiometry and affinity in the solution remain elusive. Our aim was to characterize the gal-1–anginex interaction via isothermal titration calorimetry. In order to ensure protein purity and integrity, native gel electrophoresis, Western blot analysis, mass spectrometric measurements, and ultracentrifugation were carried out for the recombinant wild-type human gal-1 and V5D gal-1 expressed in E. coli. Two stages were identified in the titration curves: (i) formation of a 4:1 galectin-1–anginex complex with low nM affinity, and (ii) a complex with 1:1 stoichiometry exhibiting KD > 200 nM. The 4:1 complex was robust at different concentrations, and neither the oxidation state nor the V5D mutation (a monomeric gal-1 mutant) of gal-1 affected this stoichiometry. The presence of the high-affinity 4:1 interaction may have implications for the biological applications of anginex.
引用
收藏
页码:449 / 456
页数:7
相关论文
共 152 条
[61]  
Bianco GA(undefined)undefined undefined undefined undefined-undefined
[62]  
Ilarregui JM(undefined)undefined undefined undefined undefined-undefined
[63]  
Toscano MA(undefined)undefined undefined undefined undefined-undefined
[64]  
Rabinovich GA(undefined)undefined undefined undefined undefined-undefined
[65]  
Lopez-Lucendo MF(undefined)undefined undefined undefined undefined-undefined
[66]  
Solis D(undefined)undefined undefined undefined undefined-undefined
[67]  
Andre S(undefined)undefined undefined undefined undefined-undefined
[68]  
Hirabayashi J(undefined)undefined undefined undefined undefined-undefined
[69]  
Kasai K(undefined)undefined undefined undefined undefined-undefined
[70]  
Kaltner H(undefined)undefined undefined undefined undefined-undefined